The multiple worlds of genetically manipulated laboratory organisms such as transgenic mice or worms with certain gene mutations are somewhat reminiscent of parallel worlds in quantum mechanics. So are various models of aging tested in such organisms. In this context, the tumor suppressor p53 has been found to either accelerate or delay aging, the latter, for instance, in conjunction with ARF, another tumor suppressor, as shown very recently. To more easily determine which of these artificial settings comes closest to real life, I discuss here their features in the light of my protein structure-based insights that have led me to propose a physiological antiaging role for the retinoblastoma tumor suppressor protein (RB) over the past four years.
to an oncogene-initiated neoplastic transformation (1) . In this context, these investigators also qualified the tumor suppressor p53 as an "oncogene-induced senescence effector" (1) . As such, this study supported the widely held view according to which the processes of cancer and aging exclude one another or yet that the sense of aging is to oppose the occurrence of neoplasias (2).
This month, however, Serrano et al. (3) communicated results that contradict the alleged dichotomy between senescence and cancer, yet they failed to quote their own paper of 2005 and explained the obvious data contradiction by different experimental conditions. Specifically, these investigators attributed those previous cases in which p53 had previously been found to accelerate aging to its "permanent activation" (3)-due to "truncation of p53 domains or constitutive endogenous damage" (3)-whereas their own results of this month led them to assume that increasing the activity of ("normally regulated") p53 produces delayed aging (3).
Moreover, they showed data implying that p53 cooperates with ARF, which is another important tumor suppressor, in delaying aging (3).
Yet, these interpretations per se cannot solve the underlying puzzle as to which of the discussed observations on p53 is ultimately correct in terms of reflecting normal physiology since all of them are based on data obtained with genetically manipulated and thus abnormal mice. It follows that, by definition, p53 or any other gene product cannot be "normally regulated" in such animals. Nevertheless, some of these models may represent an useful approximation of biological events in real life, but in order to determine which of these models complies with reality one needs to take into account additional considerations. This framework should help establish the roles of p53 and ARF in natural senescence. Given that it is known that RB acts as a downstream effector for both p53 (10, 11) and ARF (12) to inhibit cell cycle progression and, as a result, to prevent cancer, it is conceivable that the anti-aging effects of p53 and ARF now observed in experimental models (1) have been mediated by RB, thus lending further support to the notion that RB is not only the key checkpoint in the control of cancer, but also of aging (9) . Since cancer occurs predominantly in older individuals, my present molecular insight should significantly contribute to implementing the clinical rationale of reducing the incidence of malignancies by promoting longevity.
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